Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOLD-EXT open-label extension of odevixibat in children with biliary atresia
2022-501090-39-00Phase 3Completed
- Sponsor
- Ipsen
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 3, open-label, single-arm trial of odevixibat in biliary atresia, sponsored by Ipsen. Primary endpoint: Time to liver transplant or death. Started Dec 2022; status: completed.
02
Drugs
odevixibat
03
Conditions
biliary atresia
Beyond the preview
Go deeper on 2022-501090-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501090-39-00.